1.	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: COLOGEN, NCT00138060
2.	p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ASSO OE-1, EudraCT 2006-006647-31, NCT00525200
3.	Phase IV Study of Chemoresistance Markers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CHUL-BIO-COLON, RECF0356, INCA-RECF0356, NCT00559676
4.	A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: CMNa-ESO-01-2007, NCT00642239
5.	Yunzhi as Dietary Supplement in Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: YUNZHI-BC, NCT00647075
6.	Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Phase: Phase IV Type: Supportive care Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: GLU_07, NCT00772824
7.	Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Over 21 Sponsor: Other Protocol IDs: PK01/16/08, NCT00808184
8.	Phase IV Study of the Correlation of Proteomic Signature With Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: COL-SPAM-0610, SPAM-0610, COL-IDRCB-2006-A00295-46, INCA-RECF0391, NCT00959673
9.	Skin Cancer Prevention Phase: Phase IV Type: Prevention Status: Active Age: No age specified Sponsor: Other Protocol IDs: 562, NCT00847912
10.	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: 2009-03, NCT00868569
11.	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2009-04, NCT00874406
12.	Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-13, NCT00911092
13.	Phase II/III Randomized Study of Oxaliplatin, Irinotecan, Leucovorin Calcium, and Fluorouracil Versus Gemcitabine as First-Line Chemotherapy in Patients With Metastatic Adenocarcinoma of the Pancreas Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
14.	Phase II/III Randomized Study of Fluorouracil, Cisplatin, and Radiotherapy Versus Gemcitabine Hydrochloride and Oxaliplatin in Patients With Unresectable, Nonmetastatic Cancer of the Biliary Tract Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
15.	Phase II/III Randomized Study of Radiochemotherapy Comprising the FOLFOX Regimen Versus Fluorouracil and Cisplatin (Herskovic Regimen) as First-Line Therapy in Patients With Inoperable Esophageal Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FRE-FNCLCC- ACCORD-17/0707, FRE-FNCLCC- ACCORD-17/0707, EU-20848, NCT00861094
16.	FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: STX0206, NCT00724503
17.	Phase II/III Randomized Study of Adjuvant Therapy Comprising Gemcitabine Hydrochloride With Versus Without Cisplatin, Epirubicin Hydrochloride, and Fluorouracil Followed by Chemoradiotherapy With Fluorouracil or Capecitabine in Patients With Stage IB, II, or III Adenocarcinoma of the Pancreas Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SRSI-PACT-7, PACT-7, EU-20932, NCT00960284
18.	Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial Phase: Phase III, Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: R-09-025, NCT00907543
19.	Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer Phase: Phase III, Phase II Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UKM-MRC-FOCUS3-CR12, FOCUS 3 - CR12, EUDRACT-2008-008323-15, EU-20960, NCT00975897
20.	Phase III Randomized Study of Adjuvant Induction Chemotherapy With or Without Cyclophosphamide and Methotrexate as Maintenance Chemotherapy in Patients With Stage I, II, or III Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IBCSG-22-00, EU-20119, NCT00022516, EUDRACT-2005-005666-36
21.	Phase III Randomized Study of Radiotherapy and Fluorouracil With Either Mitomycin or Cisplatin and With or Without Maintenance Therapy in Patients With Primary Epidermoid Anal Cancer Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: NCRI-ACT-II, EU-20056, UKCCCR-ACT-II, ISRCTN26715889, NCT00025090
22.	Phase III Randomized Study of Neoadjuvant Cisplatin and Fluorouracil Versus Cisplatin, Epirubicin, and Fluorouracil in Patients With Resectable Adenocarcinoma of the Esophagus Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MRC-OE05, EU-20204, NCT00041262
23.	Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-R-04, NCT00058474, CALGB-NSABP-R-04
24.	Phase III Randomized Study of Leucovorin Calcium and Fluorouracil With or Without Oxaliplatin Versus Capecitabine With or Without Oxaliplatin in Patients With Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: NCRI-FOCUS2, MRC-CR09, EU-20303, NCT00070213
25.	Phase III Randomized Study of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (Note: All Treatment Arms Containing Irinotecan Closed to Accrual as of 6/1/2005) Phase: Phase III Type: Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: NCCTG-N0147, ECOG-N0147, N0147, NCT00079274